CMG Ingredient Spotlight March 2026: NMN
Welcome to the CMG Ingredient Spotlight for March 2026. This edition focuses on nicotinamide mononucleotide (NMN), a bioactive nucleotide that has attracted considerable attention in recent years for its potential as a therapeutic agent in addressing age-related health conditions. March has also been a productive month for NMN, with several key articles published. In this […]
Article: A Spotlight on Nicotinamide Mononucleotide (NMN)
In March, a journal article on NMN by Dr Brad McEwen PhD was published, titled “A Spotlight on Nicotinamide Mononucleotide (NMN)”. It was published in the peer-reviewed journal Australasian Journal of Natural Medicine. This article discussed the preclinical research of NMN, including enhancing NAD+ biosynthesis, increasing intracellular NAD+ levels, and improving mitochondrial bioenergetics, cellular energy […]
CMG Breaking News: Nicotinamide mononucleotide (NMN) now permitted in Australia
Welcome to CMG Breaking News: Nicotinamide mononucleotide (NMN) now permitted in Australia Nicotinamide mononucleotide (NMN) is now a permitted ingredient for Listed Medicines (AUST L) and Assessed Listed Medicines (AUST L(A)) in Australia. Introduction Nicotinamide mononucleotide (NMN) is a bioactive nucleotide that has amassed significant attention in recent years due to its potential as a […]